Oragenics, Inc. Reaches Agreement for North American Representation of Teddy's Pride(R) Oral Care Probiotics Through SLA Brands
Nov. 29, 2010 (Business Wire) -- Florida-based biopharmaceutical company Oragenics, Inc. (OTCBB: ORNI) (www.oragenics.com) has announced that its oral care probiotic for cats and dogs, Teddy’s Pride® (www.teddyspride.com), will be represented by Schiaffino, Lasky & Associates, Inc. (SLA Brands) to pet product distributors and retailers in the United States and Canada.
“We are pleased with the opportunity to bring our ProBiora3® oral care products for pets, Teddy’s Pride®, to pet product retailers in the United States and Canada through SLA Brands,” said Gerry David, Executive Vice President, Sales and Marketing for Oragenics. “We believe SLA Brands has a well established network of distributors and pet product retailers throughout North America which can provide greater market exposure for Teddy’s Pride.”
“We are looking forward to partnering with Oragenics for the distribution of Teddy’s Pride oral care probiotics for cats and dogs to the pet stores and distributors we work with in both the United States and in Canada,” said Mike Lasky, Managing Partner, SLA Brands, Inc. “Our partners rely upon us to provide innovative new products that are all-natural and of the highest quality. Teddy’s Pride is expected to be an excellent fit.”
Bill Schiaffino, SLA founder and managing partner, said recently: “With the pet sector launch of Oragenics’ patented ProBiora3 probiotic dental care formulation, I foresee a swing in the pet dental care retail market away from the old style and difficult to use tooth brushes, cleaners and wipes to Teddy’s Pride, as it is easy to use and a more effective long- term solution to pet dental care and bad breath management.”
ProBiora3, the active ingredient in Oragenics' probiotic products, naturally supports gum and tooth health while freshening breath and whitening teeth. ProBiora3® technology was developed by Oragenics' Chief Scientific Officer, Dr. Jeffrey Hillman, D.M.D., Ph.D., during more than 25 years of research, which began at the Harvard-affiliated Forsyth Institute in Boston and continued at the University of Florida. This technology has only recently become available to the general public. ProBiora3® contains three strains of beneficial bacteria that help maintain a healthy microbial balance in the mouth. It is 100% natural and is made in the USA in an FDA-registered and GMP-certified facility.
About Oragenics, Inc.
Oragenics is a biopharmaceutical company focused primarily on oral health products and novel antibiotics. Within oral health, Oragenics is developing its pharmaceutical product candidate, SMaRT Replacement Therapy™, and also commercializing its oral probiotic product, ProBiora3. Within antibiotics, Oragenics is developing a pharmaceutical candidate, MU1140-S™ and intends to use its patented, novel organic chemistry platform to create additional antibiotics for therapeutic use.
About SLA Brands, Inc.
Schiaffino & Associates was founded in 2003 to serve the pet industry in the United States and Canada. With the addition of Mike Lasky as a senior partner, Schiaffino & Associates became Schiaffino, Lasky & Associates (SLA) in 2006. SLA serves as the exclusive representative for some 30 pet products manufacturers to pet distributors, retail chains, catalog and Internet accounts throughout North America as well as to several major mass market chains. SLA numbers among its client companies some of the leading pet product brands in the industry.
Safe Harbor Statement: Under the Private Securities Litigation Reform Act of 1995: This release includes forward-looking statements that reflect the Company’s current views with respect to future events and financial performance. These forward-looking statements are based on management’s beliefs and assumptions and information currently available. The words “believe,” “expect,” “anticipate,” “intend,” “estimate,” “project” and similar expressions that do not relate solely to historical matters identify forward-looking statements. Investors should be cautious in relying on forward-looking statements because they are subject to a variety of risks, uncertainties, and other factors that could cause actual results to differ materially from those expressed in any such forward-looking statements. These factors include, but are not limited to (i) the actual suitability of ProBiora3® for inclusion in other products, and (ii) our ability to successfully incorporate ProBiora3® into other products, as well as those set forth in our most recently filed annual report on Form 10-K and quarterly report on Form 10-Q, and other factors detailed from time to time in filings with the U.S. Securities and Exchange Commission. We expressly disclaim any responsibility to update forward-looking statements.
MEDIA CONTACT: For more information about Teddy’s Pride, visit www.TeddysPride.com. To schedule an interview with Dr. Hillman, contact Jennifer Zimmons at (212) 317-1400 / jzimmons@cooperglobalcommunications.com
Oragenics, Inc.
Jennifer Zimmons, 212-317-1400
jzimmons@cooperglobalcommunications.com
Source: Business Wire (November 29, 2010 - 8:00 AM EST)
News by QuoteMedia
www.quotemedia.com
AI
